CA2358495A1 - Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same - Google Patents
Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same Download PDFInfo
- Publication number
- CA2358495A1 CA2358495A1 CA002358495A CA2358495A CA2358495A1 CA 2358495 A1 CA2358495 A1 CA 2358495A1 CA 002358495 A CA002358495 A CA 002358495A CA 2358495 A CA2358495 A CA 2358495A CA 2358495 A1 CA2358495 A1 CA 2358495A1
- Authority
- CA
- Canada
- Prior art keywords
- microsphere
- release
- releasing hormone
- luteinizing hormone
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
There is disclosed a prolonged release microsphere which can constantly release medicinal drugs, such as luteinizing hormone-releasing hormone analogues and encapsulate them at high content rates. It is prepared by dissolving a copolymer of lactide and gycolide in methylene chloride, dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent, combining the above two solutions with each other to produce an emulsion phase, dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system, removing the combined solvent of the emulsion phase to generate a polymeric microsphere; freeze-drying the polymeric microsphere. The microsphere prepared has a much finer inner structure, by virtue of which the microsphere is secured in a constant release rate. The single emulsion system which simplifies the preparation, allows for the maintenance of a drug content of 10 % or more. The charged groups of the release-controlling materials associated with the polymers minimize the excess release of the oppositely charged drugs at an initial stage, playing an important role in keeping the release rate constant.
Description
PROLONGED RELEASE MICROSPHERE ENCAPSULATING
AND METHOD FOR PREPARING THE SAME
Technical Field The present invention relates to a microsphere encapsulating luteinizing hormone-releasing hormone (hereinafter referred to as "LHRH") analogues, which is able to constantly release them for a long period of time. Also, the present invention is concerned with a method for preparing such a prolonged release microsphere.
Background Art Physiologically, when testosterone or estrogen is in a low concentration level in blood or when hypothalamic-releasing hormone is stimulated, gonadotropin-releasing hormone (hereinafter referred to as "GnRH ") is secreted from the hypothalamus. The GnRH is then transferred through the hypothalamic-pituitary portal system to the pituitary gland at which the GnRH stimulates the synthesis and secretion of luteinizing hormone (hereinafter referred to as "LH ") and follicle stimulating hormone. As a result, testosterone or estrogen is secreted.
LHRH analogues act on the pituitary gland to inhibit the secretion of LH, thus resulting in the antagonizing of the liberation of testosterone and estrogen into the bloodstream. By taking advantage of this antagonistic action, the diseases caused by testosterone and estrogen, such as prostatic cancer, breast cancer, endometriosis and the like, have recently been therapeutically treated.
Like general peptide drugs, LHRH is, however, very instable within the gastro-intestinal tract and shows a low uptake efficiency therein.
Therefore, the administration of LHRH has been usually performed via injection. The administration via injection also has a significant disadvantage of being very poor in bioavailibility so that LHRH is required to be injected daily. Such injection administration also requires a long cure period, which causes a problem in a patient's adaptation to the drug, therapeutic efficiency, and treatment.
Extensive research has been made on the use of poly(lactide-co-glycolide) (PLGA), which is an intravital degradable polymer, in controlled releasable dosage forms which contain proteins or peptides.
The released form and structural stability of proteins with high molecular weights are the most difficult barriers in commercializing them into medicinal drugs. In result, research efforts have been and continue to be directed to the development of various additives and new preparation processes by which the proteins can be commercialized while maintaining their activity.
For peptide drugs, commercialization is relatively easy because peptides are smaller in size and stabler than proteins. As commercialized examples, there are sustained-release DOS preparations containing LHRH
analogues, which are peptides with a molecular weight of 1.2 kDa.
The microspheres made of PLGA are decomposed into lactic acid and glycolic acid by hydrolysis in the body and metabolized. In other words, PLGA is not harmful to the human body nor shows side effects from the decomposed products. What is better, the microspheres made of PLGA can release their contents, e.g. therapeutically effective ingredients, at a constant rate for a desired period of time.
In this regard, U.S. Pat. No. 4,711,782 introduces a technique for producing microporous microcapsules from similar polymers by W/O/W
(water in oil in water) double emulsification. This technique is usually used to capsulate water-soluble drugs. In this technique, when a water soluble drug is dissolved in water, gelatin is used together to retain the drug, and this aqueous layer is dispersed in an organic layer containing the polymer with the aid of a homogenizer, so as to give a primary emulsion. Again, this primary emulsion is dispersed in water containing polyvinyl alcohol as a surfactant, to give a secondary emulsion. The organic solvent is diffused into the aqueous layer and evaporated, so that the polymer is solidified to form the microcapsules. They are then freeze dried.
As mentioned, water is used to dissolve water-soluble peptides and the microcapsules obtained are of porous structure. Thus, these microcapsules have a problem of being so high in the initial release rate of peptide drugs and low in drug content.
AND METHOD FOR PREPARING THE SAME
Technical Field The present invention relates to a microsphere encapsulating luteinizing hormone-releasing hormone (hereinafter referred to as "LHRH") analogues, which is able to constantly release them for a long period of time. Also, the present invention is concerned with a method for preparing such a prolonged release microsphere.
Background Art Physiologically, when testosterone or estrogen is in a low concentration level in blood or when hypothalamic-releasing hormone is stimulated, gonadotropin-releasing hormone (hereinafter referred to as "GnRH ") is secreted from the hypothalamus. The GnRH is then transferred through the hypothalamic-pituitary portal system to the pituitary gland at which the GnRH stimulates the synthesis and secretion of luteinizing hormone (hereinafter referred to as "LH ") and follicle stimulating hormone. As a result, testosterone or estrogen is secreted.
LHRH analogues act on the pituitary gland to inhibit the secretion of LH, thus resulting in the antagonizing of the liberation of testosterone and estrogen into the bloodstream. By taking advantage of this antagonistic action, the diseases caused by testosterone and estrogen, such as prostatic cancer, breast cancer, endometriosis and the like, have recently been therapeutically treated.
Like general peptide drugs, LHRH is, however, very instable within the gastro-intestinal tract and shows a low uptake efficiency therein.
Therefore, the administration of LHRH has been usually performed via injection. The administration via injection also has a significant disadvantage of being very poor in bioavailibility so that LHRH is required to be injected daily. Such injection administration also requires a long cure period, which causes a problem in a patient's adaptation to the drug, therapeutic efficiency, and treatment.
Extensive research has been made on the use of poly(lactide-co-glycolide) (PLGA), which is an intravital degradable polymer, in controlled releasable dosage forms which contain proteins or peptides.
The released form and structural stability of proteins with high molecular weights are the most difficult barriers in commercializing them into medicinal drugs. In result, research efforts have been and continue to be directed to the development of various additives and new preparation processes by which the proteins can be commercialized while maintaining their activity.
For peptide drugs, commercialization is relatively easy because peptides are smaller in size and stabler than proteins. As commercialized examples, there are sustained-release DOS preparations containing LHRH
analogues, which are peptides with a molecular weight of 1.2 kDa.
The microspheres made of PLGA are decomposed into lactic acid and glycolic acid by hydrolysis in the body and metabolized. In other words, PLGA is not harmful to the human body nor shows side effects from the decomposed products. What is better, the microspheres made of PLGA can release their contents, e.g. therapeutically effective ingredients, at a constant rate for a desired period of time.
In this regard, U.S. Pat. No. 4,711,782 introduces a technique for producing microporous microcapsules from similar polymers by W/O/W
(water in oil in water) double emulsification. This technique is usually used to capsulate water-soluble drugs. In this technique, when a water soluble drug is dissolved in water, gelatin is used together to retain the drug, and this aqueous layer is dispersed in an organic layer containing the polymer with the aid of a homogenizer, so as to give a primary emulsion. Again, this primary emulsion is dispersed in water containing polyvinyl alcohol as a surfactant, to give a secondary emulsion. The organic solvent is diffused into the aqueous layer and evaporated, so that the polymer is solidified to form the microcapsules. They are then freeze dried.
As mentioned, water is used to dissolve water-soluble peptides and the microcapsules obtained are of porous structure. Thus, these microcapsules have a problem of being so high in the initial release rate of peptide drugs and low in drug content.
Disclosure of the Invention The intensive and thorough research on a prolonged release microsphere, repeated by the inventors aiming to release peptide drugs continuously for an extended period of time, resulted in the finding that, when an appropriate combination of two poly(lactide-co-glycolide) copolymers, which have an equimolar ratio between their lactide moiety and glycolide moiety and have a carboxyl group and a dodecyl group at their ends, is used as a carrier for drug, the microsphere is enhanced in biodegradation rate as well as in drug content. The negative charge of the carboxyl group attached to the end of the biodegradable polymer form an ion bond with the positive charges that the peptide drugs possess, increasing the drug content in the microsphere and preventing the drugs from being released excessively at an initial time due to diffusion. The dodecyl group plays an important role in controlling the degradation rate of the microsphere. Consequently, the microspheres in the body release LHRH analogues continuously to maintain the concentration of testosterone and estrogen in blood for an extended period of time, so as to improve the therapeutic efficiency of and the patient's adaptation to the drugs.
Therefore, it is an object of the present invention to provide a prolonged release microsphere which can control the release of drugs for a sustained period of time.
It is another object of the present invention to provide a prolonged release microsphere which is high in the content of therapeutically effective ingredients.
It is a further object of the present invention to provide a method for preparing such a prolonged release microsphere with ease and a good efficiency.
In accordance with an aspect of the present invention, there is provided a prolonged released microsphere, which is composed of a poly(lactide-co-glycolide) copolymer and encapsulate a luteinizing hormone-releasing hormone analogue.
In accordance with another aspect of the present invention, there is provided a method for preparing a prolonged release microsphere, comprising the steps of: dissolving a copolymer of lactide and glycolide in methylene chloride; dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent; combining the above two solutions with each other to produce an emulsion phase; dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system; removing the combined solvent of the emulsion phase to generate a polymeric microsphere; and freeze-drying the polymeric microsphere.
Best Modes for Carrying Out the Invention In the present invention, a microsphere which retains therapeutically effective drugs and continuously releases them for a sustained period of time, is prepared from a mixture of biodegradable polymers. As therapeutically effective drugs, LHRH analogues are of particular interest. Therefore, if the microspheres retaining LHRH
analogues are administered, they release the drugs for a long period of time, whereby testosterone or estrogen can be maintained at a low level in the blood and an improvement in therapeutic effect and patient's adaptation to the drugs can be brought about.
The prolonged release microsphere which encapsulates LHRH
analogues has an aporous, fine and uniform inner structure, so that its drug content rate is enhanced.
The microsphere can be prepared in a single emulsion process. In detail, LHRH analogues, including goserelin acetate, nafarelin acetate, buserelin acetate and leuprorelin acetate, are dissolved in a subsidiary solvent and added to an organic solvent containing a polymer to give an oil phase which is then dispersed in an aqueous phase.
A preferred example of the organic solvent useful in the invention is methylene chloride. The aqueous phase is obtainable by dissolving polyvinyl alcohol.
The subsidiary solvent which dissolves LHRH should be miscible with the organic solvent (methylene chloride) and water, both. Examples of the subsidiary solvent include N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), acetone, ethanol, ethyl acetate, and methyl ethyl ketone (MEK) with the most preference to NMP. 'This subsidiary solvent plays an important role in providing the microsphere with an aporous fine structure.
In the present invention, the release of LHRH analogues is controlled in a double manner by the actions of the functional groups, i.e.
carboxyl group and dodecyl group, attached to the ends of the two polymers which compose the microsphere. The carboxyl group forms a hydrophobic ion pair with LHRH analogues, so the release rate thereof is retarded. The dodecyl group inhibits the enzymatic action to degrade the microsphere, so the integrity of the biodegradable microsphere is sustained. Therefore, the drug contained in the microsphere is bot released in a sudden burst.
The compound suitable to retard the release rate of LHRH
analogues must form the hydrophobic ion pair with LHRH analogues as well as can be dissolved in the organic solvent. Preferable examples to meet these standards include sodium oleate, deoxycholic acid, cholic acid, fatty acids and phosphatidic acids.
The biodegradable microsphere of the present invention is aporous with an ultrafine inner structure, as shown in Figs. l and 2. The data obtained from an in vitro release test demonstrate that LHRH is released at relatively constant rates from the microspheres of the invention, as shown in Fig. 3. The microspheres were measured for their weight loss in order to obtain the information about their biodegradation rates, which finally told that the microspheres are completely decomposed on around the 45th day after testing, as shown in Fig. 4. The data obtained from an in vivo release test, shown in Fig. 5, are well correlated with those of Fig.
4.
A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
EXAMPLE I : Preparation of Biodegradable Microsphere Containing Leuprorelin acetate A microsphere was made from biodegradable PLGA in an O/W (oil in water) mono-emulsification method.
In 3 ml of methylene chloride was dissolved 350 mg of each of a PLGA which has a dodecyl group at its end and a molecular weight of 12,000 with 50:50 lactide moiety:glycolide moiety, such as that sold by Boehringer Ingelheim under the brand name of RH502, and a PLGA
which has a carboxyl group at its end and a molecular weight of 8,600 with 50:50 lactide moiety:glycolide moiety, such as that sold by Boehringer Ingelheim under the brand name of RH502H. This methylene chloride solution was sufficiently mixed with a solution of 100 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.5 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 700 rpm for 30 min.
While the emulsion was stirred for 3 hours under an atmosphere, N-methyl-2-pyrrolidone was extracted with water and methylene chloride was evaporated out, so as to give solidified microspheres. After being collected by centrifugation at 8,000 rpm for 30 min, the microspheres were centrifuged again twice with water to remove remaining solvent and drugs and then, freeze-dried.
EXAMPLE II : Preparation of Biodegradable Microsphere Containing Goserelin acetate In 3 ml of methylene chloride were dissolved 100 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 25 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 200 ml of a solution of 0.3 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE III: Preparation of Biodegradable Microsphere Containing Nafarelin acetate In 5 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 50 mg of nafarelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 500 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE IV: Preparation of Biodegradable Microsphere Containing Leuprorelin Acetate using Homogenizes In 5 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 50 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.5 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE V: Preparation of Biodegradable Microsphere Containing Leuprorelin acetate with Sodium Oleate In 1 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of SO mg of leuprorelin acetate and 3.105 mg of sodium oleate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE VI: Preparation of Biodegradable Microsphere Containing Sodium Oleate/Leuprorelin Complex 17.5 mg of sodium oleate and 50 mg of leuprorelin acetate were reacted in distilled water to yield precipitates which were, then, collected and freeze-dried. They were dissolved in a mixed solution of 0.66 ml of N-methyl-2-pyrrolidone and 1.33 ml of methylene chloride which contained 200 mg of each of RG502H and RG502. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the _g_ remaining procedure of Example I.
Drug Content and Average Particle Size of the Microsphere Avg. Particle Examples Drug Content Size (,um) I 10.76 138.5 II 9.98 106.8 III 10.21 122.1 IV 10.71 11.2 V 10.32 10.6 VI 11.21 10.4 TEST EXAMPLE I: in vitro Drug Release of Microspheres The biodegradable microspheres prepared in Examples were tested for in vitro release as follows. 5 mg of the freeze-dried microsphere were dispersed in a vial containing a solution of 0.05% Tween 80 in 10 ml of a 0.333 M phosphate buffer and stored at 37 °C for 28 days. A test sample was taken every third day from the first day to the thirtieth day.
The ten samples thus taken were centrifuged. After the removal of the supernatant, the microspheres were quantified for the drugs through an HPLC with a mobile phase of 3:1 ammonium acetate:methanol at a flow rate of 1.0 ml/min at 280 nm. The results were shown in Fig. 3.
TEST EXAMPLE II: Degradation of Microspheres Under the same condition as that of Test Example I, a test sample was taken every forth day. The samples were centrifuged, followed by the removal of the supernatant. The microspheres thus obtained were dried and accurately measured for their weights. From the measurements, the degradation rates of the microspheres were calculated, and shown in Fig. 4.
TEST EXAMPLE III: in vivo Drug Release of Microspheres The biodegradable microspheres prepared in Examples were tested for in vitro release as follows. The microspheres were introduced into the femoral regions of rats via intramuscular injection and the remaining microspheres were taken from the femoral regions by incising the regions every fifth day. The microspheres taken were homogenized in 10 ml of a solution of 0.02 wt% Tween 80 (polyoxyethylene 20 oleate, Junsei Chemical Co.) in a 0.333 M phosphate buffer (pH 7.0). After further addition of 10 ml of the buffer and 10 ml of methylene chloride, the drugs were extracted in an aqueous layer. These extracts were quantified by HPLC under the same condition as that of the in vitro release test and the results are shown in Fig. 5.
Brief Description of the Drawings Fig. 1 is an SEM photograph showing the microsphere of the present invention;
Fig. 2 is an SEM photograph showing a cross section of the microsphere of the present invention.
Fig. 3 is a plot showing the in vitro release rates of the microspheres against time.
Fig. 4 is a plot showing the weight loss rates of the microspheres against time.
Fig. 5 is a plot showing the in vivo release rates of the microspheres against time.
Industrial Applicability As described hereinbefore, the microspheres prepared according to the present invention have much finer inner structures than do conventional microspheres, by virtue of which the microspheres are secure in a constant release rate. The single emulsion system of the present invention simplifies the preparation process of the microsphere, enabling it to maintain a drug content of 10% or more. In addition, the charged groups of the release-controlling materials associated with the polymers minimize the excess release of the oppositely charged drugs at an initial stage, playing an important role in keeping the release rate constant.
The present invention has been described in an illustrative manner, and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Therefore, it is an object of the present invention to provide a prolonged release microsphere which can control the release of drugs for a sustained period of time.
It is another object of the present invention to provide a prolonged release microsphere which is high in the content of therapeutically effective ingredients.
It is a further object of the present invention to provide a method for preparing such a prolonged release microsphere with ease and a good efficiency.
In accordance with an aspect of the present invention, there is provided a prolonged released microsphere, which is composed of a poly(lactide-co-glycolide) copolymer and encapsulate a luteinizing hormone-releasing hormone analogue.
In accordance with another aspect of the present invention, there is provided a method for preparing a prolonged release microsphere, comprising the steps of: dissolving a copolymer of lactide and glycolide in methylene chloride; dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent; combining the above two solutions with each other to produce an emulsion phase; dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system; removing the combined solvent of the emulsion phase to generate a polymeric microsphere; and freeze-drying the polymeric microsphere.
Best Modes for Carrying Out the Invention In the present invention, a microsphere which retains therapeutically effective drugs and continuously releases them for a sustained period of time, is prepared from a mixture of biodegradable polymers. As therapeutically effective drugs, LHRH analogues are of particular interest. Therefore, if the microspheres retaining LHRH
analogues are administered, they release the drugs for a long period of time, whereby testosterone or estrogen can be maintained at a low level in the blood and an improvement in therapeutic effect and patient's adaptation to the drugs can be brought about.
The prolonged release microsphere which encapsulates LHRH
analogues has an aporous, fine and uniform inner structure, so that its drug content rate is enhanced.
The microsphere can be prepared in a single emulsion process. In detail, LHRH analogues, including goserelin acetate, nafarelin acetate, buserelin acetate and leuprorelin acetate, are dissolved in a subsidiary solvent and added to an organic solvent containing a polymer to give an oil phase which is then dispersed in an aqueous phase.
A preferred example of the organic solvent useful in the invention is methylene chloride. The aqueous phase is obtainable by dissolving polyvinyl alcohol.
The subsidiary solvent which dissolves LHRH should be miscible with the organic solvent (methylene chloride) and water, both. Examples of the subsidiary solvent include N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), acetone, ethanol, ethyl acetate, and methyl ethyl ketone (MEK) with the most preference to NMP. 'This subsidiary solvent plays an important role in providing the microsphere with an aporous fine structure.
In the present invention, the release of LHRH analogues is controlled in a double manner by the actions of the functional groups, i.e.
carboxyl group and dodecyl group, attached to the ends of the two polymers which compose the microsphere. The carboxyl group forms a hydrophobic ion pair with LHRH analogues, so the release rate thereof is retarded. The dodecyl group inhibits the enzymatic action to degrade the microsphere, so the integrity of the biodegradable microsphere is sustained. Therefore, the drug contained in the microsphere is bot released in a sudden burst.
The compound suitable to retard the release rate of LHRH
analogues must form the hydrophobic ion pair with LHRH analogues as well as can be dissolved in the organic solvent. Preferable examples to meet these standards include sodium oleate, deoxycholic acid, cholic acid, fatty acids and phosphatidic acids.
The biodegradable microsphere of the present invention is aporous with an ultrafine inner structure, as shown in Figs. l and 2. The data obtained from an in vitro release test demonstrate that LHRH is released at relatively constant rates from the microspheres of the invention, as shown in Fig. 3. The microspheres were measured for their weight loss in order to obtain the information about their biodegradation rates, which finally told that the microspheres are completely decomposed on around the 45th day after testing, as shown in Fig. 4. The data obtained from an in vivo release test, shown in Fig. 5, are well correlated with those of Fig.
4.
A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
EXAMPLE I : Preparation of Biodegradable Microsphere Containing Leuprorelin acetate A microsphere was made from biodegradable PLGA in an O/W (oil in water) mono-emulsification method.
In 3 ml of methylene chloride was dissolved 350 mg of each of a PLGA which has a dodecyl group at its end and a molecular weight of 12,000 with 50:50 lactide moiety:glycolide moiety, such as that sold by Boehringer Ingelheim under the brand name of RH502, and a PLGA
which has a carboxyl group at its end and a molecular weight of 8,600 with 50:50 lactide moiety:glycolide moiety, such as that sold by Boehringer Ingelheim under the brand name of RH502H. This methylene chloride solution was sufficiently mixed with a solution of 100 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.5 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 700 rpm for 30 min.
While the emulsion was stirred for 3 hours under an atmosphere, N-methyl-2-pyrrolidone was extracted with water and methylene chloride was evaporated out, so as to give solidified microspheres. After being collected by centrifugation at 8,000 rpm for 30 min, the microspheres were centrifuged again twice with water to remove remaining solvent and drugs and then, freeze-dried.
EXAMPLE II : Preparation of Biodegradable Microsphere Containing Goserelin acetate In 3 ml of methylene chloride were dissolved 100 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 25 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 200 ml of a solution of 0.3 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE III: Preparation of Biodegradable Microsphere Containing Nafarelin acetate In 5 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 50 mg of nafarelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a stirrer at 500 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE IV: Preparation of Biodegradable Microsphere Containing Leuprorelin Acetate using Homogenizes In 5 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of 50 mg of leuprorelin acetate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.5 wt% polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE V: Preparation of Biodegradable Microsphere Containing Leuprorelin acetate with Sodium Oleate In 1 ml of methylene chloride were dissolved 200 mg of each of RG502H and RG502. This methylene chloride solution was sufficiently mixed with a solution of SO mg of leuprorelin acetate and 3.105 mg of sodium oleate in 1 ml of N-methyl-2-pyrrolidone. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the remaining procedure of Example I.
EXAMPLE VI: Preparation of Biodegradable Microsphere Containing Sodium Oleate/Leuprorelin Complex 17.5 mg of sodium oleate and 50 mg of leuprorelin acetate were reacted in distilled water to yield precipitates which were, then, collected and freeze-dried. They were dissolved in a mixed solution of 0.66 ml of N-methyl-2-pyrrolidone and 1.33 ml of methylene chloride which contained 200 mg of each of RG502H and RG502. To the saturated solution with the polymer and the drug, 250 ml of a solution of 0.3 wt%
polyvinyl alcohol in distilled water containing 2 g of methylene chloride was added and, then, emulsified by using a homogenizes at 700 rpm for 30 min. Thereafter, microspheres were prepared by following the _g_ remaining procedure of Example I.
Drug Content and Average Particle Size of the Microsphere Avg. Particle Examples Drug Content Size (,um) I 10.76 138.5 II 9.98 106.8 III 10.21 122.1 IV 10.71 11.2 V 10.32 10.6 VI 11.21 10.4 TEST EXAMPLE I: in vitro Drug Release of Microspheres The biodegradable microspheres prepared in Examples were tested for in vitro release as follows. 5 mg of the freeze-dried microsphere were dispersed in a vial containing a solution of 0.05% Tween 80 in 10 ml of a 0.333 M phosphate buffer and stored at 37 °C for 28 days. A test sample was taken every third day from the first day to the thirtieth day.
The ten samples thus taken were centrifuged. After the removal of the supernatant, the microspheres were quantified for the drugs through an HPLC with a mobile phase of 3:1 ammonium acetate:methanol at a flow rate of 1.0 ml/min at 280 nm. The results were shown in Fig. 3.
TEST EXAMPLE II: Degradation of Microspheres Under the same condition as that of Test Example I, a test sample was taken every forth day. The samples were centrifuged, followed by the removal of the supernatant. The microspheres thus obtained were dried and accurately measured for their weights. From the measurements, the degradation rates of the microspheres were calculated, and shown in Fig. 4.
TEST EXAMPLE III: in vivo Drug Release of Microspheres The biodegradable microspheres prepared in Examples were tested for in vitro release as follows. The microspheres were introduced into the femoral regions of rats via intramuscular injection and the remaining microspheres were taken from the femoral regions by incising the regions every fifth day. The microspheres taken were homogenized in 10 ml of a solution of 0.02 wt% Tween 80 (polyoxyethylene 20 oleate, Junsei Chemical Co.) in a 0.333 M phosphate buffer (pH 7.0). After further addition of 10 ml of the buffer and 10 ml of methylene chloride, the drugs were extracted in an aqueous layer. These extracts were quantified by HPLC under the same condition as that of the in vitro release test and the results are shown in Fig. 5.
Brief Description of the Drawings Fig. 1 is an SEM photograph showing the microsphere of the present invention;
Fig. 2 is an SEM photograph showing a cross section of the microsphere of the present invention.
Fig. 3 is a plot showing the in vitro release rates of the microspheres against time.
Fig. 4 is a plot showing the weight loss rates of the microspheres against time.
Fig. 5 is a plot showing the in vivo release rates of the microspheres against time.
Industrial Applicability As described hereinbefore, the microspheres prepared according to the present invention have much finer inner structures than do conventional microspheres, by virtue of which the microspheres are secure in a constant release rate. The single emulsion system of the present invention simplifies the preparation process of the microsphere, enabling it to maintain a drug content of 10% or more. In addition, the charged groups of the release-controlling materials associated with the polymers minimize the excess release of the oppositely charged drugs at an initial stage, playing an important role in keeping the release rate constant.
The present invention has been described in an illustrative manner, and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Claims (8)
1. A prolonged released microsphere, which is composed of a poly(lactide-co-glycolide) copolymer and encapsulate a luteinizing hormone-releasing hormone analogue.
2. A prolonged released microsphere as set forth in claim 1, wherein the luteinizing hormone-releasing hormone analogue is selected from the groups consisting of goserelin acetate, nafarelin acetate, buserelin acetate and leuprorelin acetate.
3. A prolonged released microsphere as set forth in claim 1, wherein the copolymer consists of a polylactide and a polyglycolide either of which have a dodecyl group and a carboxyl group at their ends.
4. A method for preparing a prolonged release microsphere, comprising the steps of:
dissolving a copolymer of lactide and glycolide in methylene chloride;
dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent;
combining the above two solutions with each other to produce an emulsion phase;
dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system;
removing the combined solvent of the emulsion phase to generate a polymeric microsphere;
freeze-drying the polymeric microsphere.
dissolving a copolymer of lactide and glycolide in methylene chloride;
dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent;
combining the above two solutions with each other to produce an emulsion phase;
dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system;
removing the combined solvent of the emulsion phase to generate a polymeric microsphere;
freeze-drying the polymeric microsphere.
5. A method as set forth in claim 4, wherein the single emulsion system comprises 75.0-99.0 wt% of an aqueous phase and 0.3-0.5 wt%
of polyvinyl alcohol and the emulsion phase comprises 0.50-10.0 wt% of methylene chloride and 0.2-10.0 wt% of the subsidiary solvent.
of polyvinyl alcohol and the emulsion phase comprises 0.50-10.0 wt% of methylene chloride and 0.2-10.0 wt% of the subsidiary solvent.
6. A method as set forth in claim 4 or 5, wherein the subsidiary solvent is N-methyl-2-pyrrolidine.
7. A method as set forth in claim 5, wherein the release-controlling material is capable of hydrophobic ion paring with the luteinizing hormone-releasing hormone analogue and being dissolved in an organic solvent.
8. A method as set forth in claim 5 or 7, wherein the release-controlling material is sodium oleate and is used at an amount of 75-100 mol% based on the moles of the luteinizing hormone-releasing hormone analogue.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1998/62142 | 1998-12-30 | ||
KR1019980062142A KR100321854B1 (en) | 1998-12-30 | 1998-12-30 | Long-term sustained-release microspheres containing luteinizing hormone releasing hormone homologues and a method of producing the same |
PCT/KR1999/000071 WO2000040259A1 (en) | 1998-12-30 | 1999-02-11 | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2358495A1 true CA2358495A1 (en) | 2000-07-13 |
Family
ID=19568831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002358495A Abandoned CA2358495A1 (en) | 1998-12-30 | 1999-02-11 | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP2002534392A (en) |
KR (1) | KR100321854B1 (en) |
CN (1) | CN1348383A (en) |
AR (1) | AR017480A1 (en) |
BR (1) | BR9916945A (en) |
CA (1) | CA2358495A1 (en) |
MX (1) | MXPA01005540A (en) |
TR (1) | TR200101913T2 (en) |
WO (1) | WO2000040259A1 (en) |
ZA (1) | ZA992059B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
US20050159361A1 (en) * | 2002-03-11 | 2005-07-21 | Takahito Hara | Remedies for sex hormone-dependent disease |
CA2492339A1 (en) | 2002-06-12 | 2003-12-24 | Boston Scientific Limited | Bulking agents |
ES2605402T3 (en) | 2002-06-25 | 2017-03-14 | Takeda Pharmaceutical Company Limited | Procedure to produce a sustained release composition |
US8343513B2 (en) * | 2003-07-18 | 2013-01-01 | Oakwood Laboratories, Llc | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
BR0305373A (en) * | 2003-11-06 | 2005-06-28 | Iseu Da Silva Nunes Nelson Edu | Ammonium and magnesium phospholinoleate palmitoleate anhydride protein aggregate immunomodulator and process for obtaining and formulating it |
TW200529890A (en) | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
KR100622996B1 (en) * | 2005-03-03 | 2006-09-14 | 한국과학기술원 | Nonporous microspheres including drug and manufacturing method thereof |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
EP2299990A1 (en) * | 2008-06-09 | 2011-03-30 | Boehringer Ingelheim International GmbH | Novel embedment particles for inhalation |
PL2331075T3 (en) | 2008-08-29 | 2016-04-29 | Genzyme Corp | Controlled-released peptide formulations |
KR101663560B1 (en) * | 2009-02-13 | 2016-10-10 | 동국제약 주식회사 | Method for manufacturing uniform delayed-release microspheres |
DE102011114864A1 (en) | 2011-10-05 | 2013-04-11 | Acino Ag | Process for producing a homogeneous powder mixture and method for producing an implant and implant |
ME03532B (en) | 2011-12-14 | 2020-04-20 | Abraxis Bioscience Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US20160175313A1 (en) * | 2013-08-06 | 2016-06-23 | Dongkook Pharmaceutical Co., Ltd., | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
CN109394705B (en) * | 2018-12-04 | 2021-11-19 | 沈阳药科大学 | Goserelin sustained-release microsphere freeze-dried powder and preparation method thereof |
JP6852943B1 (en) * | 2020-05-08 | 2021-03-31 | エム・テクニック株式会社 | Microspheres in which the main agent is uniformly dispersed and sustained-release preparations containing them |
KR20220163418A (en) * | 2020-05-08 | 2022-12-09 | 엠. 테크닉 가부시키가이샤 | Microspheres in which physiologically active substances are uniformly dispersed and sustained-release preparations containing the microspheres |
CN115551485A (en) * | 2020-05-08 | 2022-12-30 | M技术株式会社 | Microspheres with uniformly dispersed physiologically active substance and sustained-release preparation containing the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
CH661206A5 (en) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES. |
CH660302A5 (en) * | 1984-10-17 | 1987-04-15 | Debiopharm Sa | HETEROGENEOUS PHASE MICRO-ENCAPSULATION PROCESS OF WATER-SOLUBLE DRUG SUBSTANCES. |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
YU48420B (en) * | 1991-03-25 | 1998-07-10 | Hoechst Aktiengesellschaft | PROCEDURE FOR OBTAINING BIOLOGICAL DEGRADABLE MICROPARTICLES WITH LONG TERM ACTION |
FR2693905B1 (en) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Process for the preparation of microspheres for the sustained release of the hormone LHRH and its analogs, microspheres and formulations obtained. |
-
1998
- 1998-12-30 KR KR1019980062142A patent/KR100321854B1/en not_active IP Right Cessation
-
1999
- 1999-02-11 JP JP2000592014A patent/JP2002534392A/en active Pending
- 1999-02-11 MX MXPA01005540A patent/MXPA01005540A/en unknown
- 1999-02-11 WO PCT/KR1999/000071 patent/WO2000040259A1/en not_active Application Discontinuation
- 1999-02-11 CN CN99815239A patent/CN1348383A/en active Pending
- 1999-02-11 TR TR2001/01913T patent/TR200101913T2/en unknown
- 1999-02-11 CA CA002358495A patent/CA2358495A1/en not_active Abandoned
- 1999-02-11 BR BR9916945-2A patent/BR9916945A/en not_active Application Discontinuation
- 1999-03-15 ZA ZA9902059A patent/ZA992059B/en unknown
- 1999-03-26 AR ARP990101361A patent/AR017480A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1348383A (en) | 2002-05-08 |
TR200101913T2 (en) | 2001-11-21 |
AR017480A1 (en) | 2001-09-05 |
KR20000045577A (en) | 2000-07-25 |
WO2000040259A1 (en) | 2000-07-13 |
ZA992059B (en) | 1999-09-27 |
BR9916945A (en) | 2001-11-06 |
KR100321854B1 (en) | 2002-08-28 |
MXPA01005540A (en) | 2004-06-22 |
JP2002534392A (en) | 2002-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2358495A1 (en) | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same | |
JP2909418B2 (en) | Delayed release microsphere of drug | |
EP0586238B1 (en) | Method of producing sustained-release microcapsules | |
EP0674506B1 (en) | Controlled release growth hormone containing microspheres | |
AU668384B2 (en) | Controlled release ACTH containing microspheres | |
NL195056C (en) | Process for the preparation of preparations containing salts of peptides with carboxy terminated polyesters. | |
EP0839525B1 (en) | Sustained-release preparation | |
NZ239381A (en) | A microcapsule designed for zero order release of a polypeptide | |
HU193910B (en) | Process for production of microcapsules giving activity in case of their soluability in water | |
JP2008525436A (en) | Controlled release composition | |
KR20100026384A (en) | Method for manufacturing delayed-release microspheres by solvent intra-exchange evaporation | |
WO2002012369A1 (en) | Lactic acid polymer and process for producing the same | |
EP1532985B1 (en) | Process for producing a sustained-release composition | |
JP2008505057A (en) | Sustained release composition, production method and use thereof | |
KR20100094227A (en) | Method for manufacturing delayed-release microspheres | |
JPH09221417A (en) | Production of controlled release preparation for injection | |
Woo et al. | In vitro characterization and in vivo testosterone suppression of 6-month release poly (D, L-lactide) leuprolide microspheres | |
KR100566573B1 (en) | Preparation method of sustained release microspheres containing LHRH analogue | |
JP2011032277A (en) | Sustained-release composition and process for production the same | |
JP2003192595A (en) | Local administration agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |